Aytu BioPharma closes $16.6M upsized public offering; EXXUA launch planned Q4 2025

AYTU BIOPHARMA, INC

Gross proceeds $16.6M from 1.37M shares at $1.50 and pre-funded warrants; overallotment fully exercised for 1.44M additional shares.
Shares outstanding post-offering: 8,976,914.
EXXUA is first-in-class oral 5HT1a receptor agonist for MDD; no sexual dysfunction warning; studied in >5,000 patients.
Conference call June 11, 2025 at 4:30 p.m. ET to detail EXXUA commercialization plan.
Net proceeds for working capital and to fund EXXUA launch; expects FDA-approved product to enter $22B U.S. MDD market.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.